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Rapid activation of the complement system by cuprophane depends on
complement component C4. Hemodialysis with cuprophane dialyzer mem-
branes promotes rapid activation of the complement system, which is
thought to be mediated by the alternative pathway. Complete hereditary
deficiency of complement C4, a classical pathway component, in two
hemodialysis patients provided the opportunity to investigate a possible
role of the classical pathway. In two hemodialysis patients with both C4
isotypes, C4A and C4B, and in one patient with C4B deficiency comple-
ment activation occurred immediately after the onset of hemodialysis, with
peak levels of C3a and terminal complement complex (TCC) after ten to
fifteen minutes. In patients with complete C4 deficiency, C3a and TCC
remained unchanged for fifteen minutes and increased thereafter, reach-
ing the highest level after thirty minutes. The leukocyte nadir was also
delayed from fifteen to thirty minutes. In vitro incubation of normal, C4A-
or C4B-deficient serum with cuprophane caused complement activation
after fifteen minutes. In contrast, no activation was observed in sera of
four C4-deficient patients. The addition of normal serum or purified
human C4 restored the capacity for rapid complement activation. In one
patient with severe immunoglobulin deficiency, C3a and TCC levels
increased only moderately after 25 minutes of cuprophane dialysis. This
patient’s serum also exhibited delayed complement activation in vitro,
which was normalized after pretreatment of cuprophane with immuno-
globulins. Preincubation of normal serum with MgEGTA, a blocker of the
classical pathway, inhibited rapid complement activation through cu-
prophane. As basal levels of C4a are markedly increased in hemodialysis
patients (3450 6 850 ng/ml) compared to healthy controls (224 6 81
ng/ml), no further elevation of C4a was detectable during cuprophane
hemodialysis. Incubation of normal serum with cuprophane, however,
caused a slight increase in C4a after five minutes. These results indicate
that the initial deposition of complement C3b on the cuprophane mem-
brane, necessary for activation of the amplification loop of the alternative
pathway, is mediated by the classical pathway C3-convertase C4b2a. We
propose an extended concept of complement activation through cu-
prophane, which is based on four steps: (a) binding of anti-polysaccharide
antibodies, (b) classical pathway activation, (c) alternative pathway acti-
vation and (d) terminal pathway activation.
Hemodialysis with cellulose membranes leads to vigorous acti-
vation of the complement system with release of the anaphylatox-
ins C3a and C5a and formation of the terminal complement
complex (TCC) [1, 2]. Complement activation commences imme-
diately after the onset of treatment [1, 2]. Both acute and chronic
sequelae of hemodialysis have been ascribed to complement
activation [3]. Acute effects include dialysis neutropenia and the
first-use syndrome with chest and back pain and shortness of
breath [4–6]. Anaphylatoxins C3a and C5a activate neutrophils
and monocytes with the release of proteases, reactive oxygen
species and arachidonic acid metabolites, and increase transcrip-
tion of interleukin (IL)-1b and tumor necrosis factor-alpha
(TNF-a) [7–9]. Complement activation may also play a role in
increased production of b2-microglobulin and amyloid bone
disease [10, 11], and the high incidence of infections and malnu-
trition [12, 13].
The complement system can be either activated by the classical
pathway, the lectin pathway or the alternative pathway. According
to current understanding, complement activation by hemodialysis
membranes is mediated exclusively by the alternative pathway.
Complement C4, a 200 kDa glycoprotein, is a major component
of the classical pathway of complement. The two C4 genes on
chromosome 6 encode for two isoforms C4A and C4B, which
differ in their physicochemical properties [14]. Two of our hemo-
dialysis patients suffer from hereditary complete C4 deficiency, an
extremely rare condition [15–17]. These two patients enabled us
to investigate a possible role of the classical pathway for comple-
ment activation during hemodialysis with cuprophane membranes
in vivo. As one of our hemodialysis patients had severe immuno-
globulin deficiency, it was also possible to study the influence of
antibodies. In vitro studies of complement activation by cu-
prophane using sera from two additional patients with complete
C4 deficiency [17] and of individuals with deficiency of C4 isotypes
C4A and C4B were performed. Levels of C4a, which is released
upon activation of C4, have not been assessed in detail in patients
undergoing hemodialysis. We therefore measured C4a during
cuprophane hemodialysis and in the in vitro system. Our investi-
gations indicate that immediate and rapid complement activation
during hemodialysis depends on the presence of immunoglobu-
lins, C4 and the classical pathway of complement.
METHODS
Patients
Patients with hereditary complete C4 deficiency. Patient 1, now a
34-year-old man, developed severe Henoch Scho¨nlein purpura at
the age of seventeen. Seven years later hemodialysis had to be
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started. He lost a renal allograft due to recurrence of disease and
chronic rejection [15]. Patients 2, 3 and 4 are siblings. They suffer
from a lupus-like illness with early onset and mesangial and
endocapillary proliferative glomerulonephritis. Patient 2, a 24-
year-old woman, recently developed end-stage renal failure. Pa-
tient 3, a 15-year-old girl, has stable renal function at a serum
creatinine of 200 mmol/liter. Patient 4, an 18-year-old boy, has a
well-functioning renal allograft [17]. All four patients are homozy-
gous for the HLA haplotype HLA A30 B18 C4AQ0 C4BQ0 DR7.
Individuals with C4A deficiency. Individual 5 is healthy. The
other two patients, 6 and 7, suffer from insulin-dependent diabe-
tes mellitus. None of our dialysis patients has C4A deficiency.
Patients with C4B deficiency. Patient 8, who is also included in
the hemodialysis studies, suffers from reflux nephropathy. Pa-
tients 9 and 10 have Wegener’s granulomatosis that is in remis-
sion.
Immunoglobulin-deficient dialysis patient. Patient 11 suffered
from chronic lymphatic leukemia with severe secondary immuno-
globulin deficiency (IgG 78 mg/dl, IgA , 10 mg/dl, IgM , 7
mg/dl). The cause of renal failure was unknown.
Patient 12 with end-stage renal disease of unknown origin and
patient 13 with arteriosclerotic nephropathy both had a normal
C4A3B1 phenotype, and were included as controls in the hemo-
dialysis experiments.
Methods
Complement C4 was phenotyped by agarose gel electrophoresis
and immunoprecipitation [18]. For quantification of C3a and C4a
the following radioimmunoassays were used: C3a des Arg 125I
RIA RPA 518, and C4a des Arg 125I RIA RPA 519 (Amersham,
UK). The terminal complement complex (TCC) was determined
by ELISA [19].
In patients with the complete C4 deficiency and in patient 11
with immunoglobulin deficiency C3, C4 and factor B were mea-
sured by standard nephelometry. Factor D and factor H were
determined by ELISA [20]. Routine hemolytic assays were used
for determination of CH50 and alternative pathway AP-CH50.
Hemodialysis studies
Hemodialysis was performed with a standard cuprophane mem-
brane (Alwall GFE 15; GAMBRO, Hechingen, Germany). All
patients received a standard heparin regimen consisting of a 2500
IU bolus and 1000 IU per hour continuously during treatment.
Blood flow was kept at 250 ml/min. For determination of com-
plement activation products ethylenediaminetetraacetate
(EDTA) blood samples were taken before the onset of treatment
and from the venous outlet of the dialyzer at 5, 10, 15, 30 and 60
minutes after blood had entered the dialyzer, and was handled as
described (immediate cooling to 4°C and centrifugation at 2000 g
for 15 min, storage at 270°C) [21]. In the C4-deficient patients
and the immunoglobulin-deficient patient additional samples
were drawn at 20 and 25 minutes. Blood for leukocyte counts was
taken at 0 and 15 minutes, when the leukocyte nadir is usually
observed, and after 30 and 45 minutes. For determination of C4a
cuprophane hemodialysis was performed in four patients having
both C4 isotypes. Two of them suffered from arteriosclerotic
nephropathy, one from diabetic nephropathy and one from anal-
gesic nephropathy. Samples were taken before and 1, 3, 5 and 10
minutes after the start of hemodialysis.
In vitro experiments
All in vitro experiments were carried out in glass tubes at 37°C.
In addition to the serum of the above-mentioned patients, sera
from four healthy individuals I to IV having both C4 isotypes were
used. All blood samples were immediately centrifuged at 4°C and
2000 g and sera stored at 270°C.
Hollow fibers of the same dialyzer as used for hemodialysis
studies were cut in 1-mm-long pieces. After taking a serum sample
at 0 minutes, 20 mg of these pieces were incubated with 1 ml of
serum. This amount ensured that enough serum could be re-
trieved from the glass tube for testing. After fifteen and then thirty
minutes of incubation, 300 ml of serum were taken and immedi-
ately stored at 270°C. Normal serum without the cuprophane
pieces was used as a negative control. The same experiments were
made with C4-deficient sera reconstituted with human C4. Fifty
microliters of purified C4 (Sigma Chemical Co., St. Louis, MO,
USA) were added to 950 ml of serum from C4-deficient patients,
resulting in a C4 concentration of 50 mg/ml. In addition, 800 ml of
serum from C4-deficient patients were mixed with 200 ml of serum
from a healthy individual with C4A3B1 phenotype, yielding a C4
concentration of 48 mg/ml. C3a and TCC were determined by the
tests described above.
To test the influence of immunoglobulins, cuprophane fibers
were preincubated for ten minutes with a polyvalent immunoglob-
ulin preparation (Pentaglobin; Biotest, Dreieich, Germany), di-
luted 1:5 in phosphate buffered saline (PBS). This solution
contained IgG 760 mg/dl, IgA 120 mg/dl and IgM 120 mg/dl. The
fibers were then centrifuged at 3000 g for five minutes, and all
excess antibodies removed and washed three times for thirty
minutes each in PBS. The pretreated cuprophane fibers were then
incubated with the serum of the immunoglobulin-deficient patient
11 as described.
To measure the effect of magnesium ethylene glycol tetra-acetic
acid (MgEGTA), an inhibitor of classical pathway activation, 8.5
ml blood of the four healthy controls were drawn directly into a
syringe containing 0.75 ml of 100 mM EGTA and 0.75 ml of 50 mM
MgCl2. These samples were then handled and incubated with
cuprophane as above.
The same incubation procedure was performed for the deter-
mination of C4a, using sera from the four healthy controls.
Samples were taken at 0, 5 and 10 minutes. C4a levels in EDTA
plasma were measured in the four healthy controls, six hemodi-
alysis patients and seven patients with chronic renal failure.
RESULTS
Complement components in patients with complete C4
deficiency
Levels of C3 and Factor H were normal. Factor B was elevated
in patients 1, 2 and 3. Factor D was increased in hemodialysis
patients 1 and 2. AP-CH50 was normal or elevated. These results
show that all C4-deficient patients had normal function of the
alternative pathway of complement. No C4 could be detected. The
classical pathway CH50 was absent or very low. Hemodialysis
patient 11 with immunoglobulin deficiency had normal C3, C4
Factor B and H levels, but factor D was increased; CH50 and
AP-CH50 were normal. Detailed concentrations are shown in
Table 1.
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Hemodialysis studies
After 15 minutes of hemodialysis with a cuprophane dialyzer
the total leukocyte counts fell to 24% and 21%, respectively, of
the predialysis count in the patients 12 and 13 with normal C4
phenotype, and to 22% in the C4B-deficient patient 8. After 30
minutes the leukocyte counts had again increased. In patients 1
and 2 with complete C4 deficiency leukocytes were unchanged at
15 minutes, fell to 19% and 29% after 30 minutes of dialysis and
increased again after 45 minutes (Fig. 1).
In the patients with normal C4 phenotype and the one with C4B
deficiency C3a levels were elevated after five minutes, reached
their maximum at 10 minutes and declined slowly thereafter. The
C4-deficient patients showed a different pattern. C3a was un-
changed and very low for up to 15 minutes and reached its peak
value at 30 minutes (Fig. 2A).
In the patients with normal C4 phenotype or C4B deficiency the
terminal complement complex increased from 5 to 10 minutes
onwards, reaching a plateau at 10 to 15 minutes. In C4-deficient
patients the TCC remained unchanged until 15 to 20 minutes,
increasing thereafter to plateau levels at 30 minutes (Fig. 2B).
These results show that complement activation in vivo and the
consecutive leukocyte drop are delayed in patients with complete
C4 deficiency.
In the patient with immunoglobulin deficiency C3a and TCC
Table 1. Complement parameters in patients with complete C4 deficiency and immunoglobulin deficiency
C3 C4 Factor B Factor D Factor H CH50 AP-CH50
mg/ml U/ml
Controls 1048 6 209 250 6 150 300 6 130 1.05 6 0.27 702 6 292 28.3 6 6.8 110 6 22
ESRD 12.1 6 3.53 750 6 272
Patient 1 1460 , 100 506 14.2 901 8.3 250
Patient 2 870 , 100 506 10.4 562 0 108
Patient 3 1190 , 100 408 1.50 780 0 152
Patient 4 1070 , 100 511 2.28 950 4 200
Patient 11 740 300 338 7.23 558 30.8 102
Patients 1–4 have a complete C4 deficiency. Patient 11 has a secondary immunoglobulin deficiency.
Fig. 1. Leukocyte counts during hemodialysis with a cuprophane mem-
brane. Whereas in control patients and in the C4B-deficient patient the
leukocyte nadir occurred after fifteen minutes, it was delayed to thirty
minutes in the two C4-deficient patients. No drop in neutrophils was
observed in the immunoglobulin-deficient patient. Symbols are: (f)
control patients with C4A3B1 phenotype (patients 12 and 13); (F)
C4B-deficient patient 8; (M) C4-deficient patient 1; (E) C4-deficient
patient 2; () immunoglobulin-deficient patient 11; for patient 11 only
neutrophil counts are shown.
Fig. 2. Levels of anaphylatoxin C3a (A) and terminal complement com-
plex (TCC) (B) during hemodialysis with a cuprophane membrane.
Compared to control patients and the C4B-deficient patient, complement
activation is delayed in the two C4-deficient patients. The immunoglobu-
lin-deficient patient shows a delayed and only weak increase in C3a and
TCC. Symbols are: (f) hemodialysis patients with both C4 isotypes
(Patients 12 and 13); (F) C4B-deficient patient (Patient 8); (M) C4-
deficient patient 1; (E) C4-deficient patient 2; () immunoglobulin-
deficient patient 11.
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remained unchanged for 25 minutes and increased only moder-
ately thereafter (Fig. 2). Due to chronic lymphatic leukemia the
patient had a total leukocyte count of 70 G/liter. The number of
neutrophils was normal (4 G/liter) and remained unchanged for
45 minutes (Fig. 1). These results indicate a profound defect of
complement activation by cuprophane in the immunoglobulin-
deficient patient. The C4a plasma levels of hemodialysis patients
are described below.
In vitro experiments
In vitro experiments were performed to confirm the dialysis data
and to investigate the influence of reconstitution of C4-deficient
sera with C4. Detailed concentrations are listed in Tables 2 and 3.
As serum capable of complement activation had to be used in
these experiments, levels of C3a at 0 minutes were already
elevated. Therefore, a significant complement activation in the
negative control without cuprophane stimulation was also ob-
served. Nevertheless, after an incubation time of 15 minutes C3a
and TCC were highly increased in serum from probands with a
normal C4 phenotype and C4A or C4B deficiency (Table 2).
C4A-deficient patients had a somewhat lower increase in C3a
compared to C4B-deficient probands (P , 0.05, unpaired t-test).
In C4-deficient serum only a marginal increase in C3a and TCC
concentrations had occurred after 15 minutes, which was compa-
rable to the negative control (Table 3). Subsequently, we investi-
gated whether the addition of purified human C4 or small
amounts of serum from a non-C4-deficient individual was able to
reconstitute the ability for rapid complement activation. Both the
Table 2. Results of C3a and terminal complement complex (TCC) after in vitro stimulation of normal, C4A-deficient, C4B-deficient and
immunoglobulin-deficient serum with cuprophane
C4 phenotype
C3a ng/ml TCC mg/ml
0 min 15 min 30 min 0 min 15 min 30 min
Negative control 430 2,580 6,800 1.2 1.6 4.6
Normal
I 430 10,330 18,160 1.2 6.5 13.0
II 1,030 9,410 23,330 0.8 3.5 5.1
III 510 14,480 22,050 1.3 4.7 14.7
IV 500 12,280 21,210 0.6 9.5 9.7
C4A-deficient
Patient 5 670 7,600 20,460 0.8 6.5 16.2
Patient 6 2,130 6,540 32,510 1.7 8.5 13.3
Patient 7 880 7,380 20,200 1.5 3.0 5.4
C4B-deficient
Patient 8 1,020 10,170 32,100 0.8 9.4 16.5
Patient 9 590 6,210 34,220 1.1 5.3 17.1
Patient 10 580 10,840 15,590 0.6 4.4 7.4
Ig-deficient
Patient 11 430 2,560 10,090 0.1 0.4 7.6
Patient 11 1 Ig 18,080 20,540 6.0 7.4
negative control: normal serum (individual I) without cuprophane stimulation
Pat. 11 1 Ig: after preincubation of cuprophane with immunoglobulins
Table 3. C3a and terminal complement complex TCC after incubation of completely C4-deficient sera with cuprophane: Effect of addition of
normal serum and purified human C4
C3a ng/ml TCC mg/ml
0 min 15 min 30 min 0 min 15 min 30 min
Patient 1
Serum 990 1,780 16,250 0.6 1.1 8.2
1 Normal seruma 24,110 29,400 10.0 11.7
1 C4b 9,030 26,060 4.8 7.8
Patient 2
Serum 300 1,150 20,020 0.3 0.5 10.6
1 Normal seruma 18,300 25,460 9.2 16.5
1 C4b 16,780 25,920 7.1 10.2
Patient 3
Serum 480 1,320 19,210 1.5 1.9 7.4
1 Normal seruma 16,090 22,310 7.8 13.5
1 C4b 24,230 n.d. 10.0 23.1
Patient 4
Serum 820 2,380 20,400 1.6 2.5 6.2
1 Normal seruma 14,990 18,450 6.2 6.2
1 C4b 11,560 20,110 3.9 9.1
ND is not determined.
a C4 concentration 48 mg/ml
b C4 concentration 50 mg/ml
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addition of C4 and serum, resulting in a C4 concentration of 50
and 48 mg/ml, respectively (normal range 200 to 500 mg/ml),
caused a rise in C3a and TCC comparable to normal controls (Fig.
3 and Table 3). These experiments confirm the in vivo results and
clearly establish that C4 deficiency is the crucial factor for delayed
complement activation. The serum of the immunoglobulin-defi-
cient patient showed an identical pattern to C4-deficient serum
with only a marginal elevation of C3a and TCC after fifteen
minutes. Preincubation of cuprophane fibers with a polyvalent
immunoglobulin preparation normalized complement activation
(Fig. 3 and Table 2).
MgEGTA-treated serum had a markedly reduced preactivation
of complement as shown by the low basal C3a levels. MgEGTA
also blocked the early increase of C3a and TCC after incubation
with cuprophane (Fig. 4). These results further establish a role of
the classical pathway in rapid complement activation by cu-
prophane in vitro.
C4a levels
In four healthy controls C4a concentrations were 224 6 81
ng/ml. Levels were 10-fold to 20-fold increased in hemodialysis
Fig. 3. Increase of (A) anaphylatoxin C3a and (B) terminal complement
complex (TCC) from 0 to 15 minutes after incubation of serum with
cuprophane. Bars show mean value and SD for each patient group. Note
that the increase in C4-deficient serum (N 5 4) and immunoglobulin-
deficient serum is similar to the increase in the negative control without
cuprophane. Addition of normal serum or purified C4 to C4-deficient
serum restores rapid complement activation. Similarly, preincubation of
cuprophane fibers with immunoglobulins normalizes activation in the
immunoglobulin-deficient serum. The difference in C3a between C4A-
deficient (N 5 3) and C4B-deficient (N 5 3) serum is significant (P , 0.05,
unpaired t-test).
Fig. 4. Influence of classical pathway activation with MgEGTA on com-
plement activation by cuprophane. Serum levels of anaphylatoxin C3a (A)
and terminal complement complex (TCC) (B) before and after twelve
minutes of incubation with cuprophane are shown. Results represent
mean 6 SD of four healthy individuals. Symbols are: (M) serum without
MgEGTA; (L) MgEGTA-treated serum. MgEGTA clearly inhibits rapid
complement activation.
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patients (3450 6 850 ng/ml) compared to controls. Intermediate
C4a values were found in six patients with various degrees of renal
failure (Fig. 5). These results show that C4a accumulates with
progressive renal failure. Because of these extremely high predi-
alysis levels, no clear changes of C4a were detectable during
hemodialysis with a cuprophan membrane. In vitro incubation of
four normal sera with cuprophane clearly led to an increase of
C4a. Basal serum values were 603 6 23 ng/ml. At five minutes C4
had increased by 198 6 30 ng/ml and after 10 minutes by 256 6
111 ng/ml. This shows that cuprophane causes moderate activa-
tion of C4, most of which occurs within the first five minutes of
incubation (Fig. 6).
DISCUSSION
The current concept of complement activation by cellulosic
hemodialysis membranes is based on an exclusive role of the
alternative complement pathway [reviewed in 22]. According to
this concept, C3(H2O)Bb, which is constantly generated in
small amounts in plasma, activates C3 to C3b, leading to
exposure of the internal thioester bond of C3. C3b then binds
to the cellulosic membrane. Binding of Factor B and its
cleavage by Factor D leads to C3bBb, the alternative pathway
C3-convertase. The convertase cleaves many more C3 mole-
cules into C3a, which is released into the fluid phase, and C3b,
which binds to the membrane surface (amplification loop). In
addition, the alternative pathway C5-convertase C3bC3bBb is
formed and cleaves C5 into C5a and C5b, thus initiating
activation of the terminal complement pathway to form the
terminal complement complex (TCC) [22]. The observation,
however, that C3b does not spontaneously bind to cellulosic
membranes, is inconsistent with this concept and indicates that
other serum factors are required for binding of C3b on the
surface [23]. It has been suggested that this additional compo-
nent is factor B, which binds primarily to the membrane and
forms a nidus for C3b [24]. Based on our observations we
propose that initial deposition of C3b on cuprophane is
mediated by the classical pathway C3-convertase C4b2a.
Our results of complement activation by cuprophane mem-
branes in patients with hereditary complete C4 deficiency clearly
show that the classical pathway C3-convertase C4b2a plays a
crucial role in the immediate complement activation after onset of
dialysis. Without a functional classical pathway C3-convertase, for
example, in a patient with complete C4 deficiency, complement
activation is delayed for about fifteen minutes. The extent of
complement activation, however, is not influenced by a defective
classical pathway.
The results obtained from our C4-deficient patients during
hemodialysis with a cuprophane dialyzer were confirmed by in
vitro studies. Complement activation by cuprophane hollow fibers
was delayed in the sera of four patients with complete C4
deficiency. Factors other than C4 may certainly have an impact on
complement activation. All patients had normal concentrations of
C3 and of the alternative pathway components, Factors B, D and
H. Most importantly, they had an unimpaired alternative pathway
hemolytic activity. The C4-deficient patients did not have signs of
active immune complex disease and circulating immune com-
plexes were undetectable. C3a levels comparable to controls
exclude a preactivation of the complement system in these
patients. The most convincing evidence, however, that C4 defi-
ciency was indeed the cause of delayed complement activation is
the fact that the addition of purified human C4 to C4-deficient
sera restored the capability for immediate complement activation.
The C4 concentrations of 50 mg/ml or 48 mg/ml in reconstituted
sera are well below the normal C4 range of 200 to 500 mg/ml.
Obviously, small amounts of C4 are therefore sufficient to trigger
complement activation. In another report of a patient with
hereditary complete C4 deficiency, delayed complement activa-
tion by zymosan, which, like cuprophane, is considered to be an
alternative pathway activator, has been described. The addition of
C4 to the serum of this patient also corrected complement
activation [25].
C4 also has a role in alternative pathway activation. Nascent
C3b binds with high affinity to C4b and is thereby protected from
cleavage by factors H and I [26]. The absence of this protective
Fig. 6. C4a serum levels upon complement activation by cuprophane in
vitro. Increments of C4a after five and ten minutes of incubation are
shown. Symbols are: (F) healthy individuals (N 5 4, mean 6 SD); (E)
negative control without cuprophane. Cuprophane causes a prompt and
slight increase in C4a serum levels.
Fig. 5. Plasma levels of anaphylatoxin C4a. Symbols are: (l) healthy
controls (N 5 4, data are mean 6 SD); (F) patients with chronic renal
failure (N 5 7); (f) hemodialysis patients (N 5 6). C4a accumulates in
renal failure. C4a levels in hemodialysis patients are 10- to 20-fold higher
than in healthy controls.
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effect may also contribute to the delayed alternative pathway
activation in patients with complete C4 deficiency.
To further substantiate a role of C4, we measured C4a, which is
released upon activation of C4 by the C1 complex, in our
hemodialysis patients. Surprisingly, we found C4a concentrations
ten to twenty times higher than those in healthy controls. Our data
of hemodialysis patients and those with various degrees of renal
insufficiency show that C4a accumulates in chronic renal failure.
Anaphylatoxins C5a [27] and most likely also C3a are cleared by
binding to their receptors on leukocytes and other cells. On the
contrary, C4a, a 9 kDa peptide, seems to be cleared by glomerular
filtration and tubular metabolization [28]. Because the anaphyla-
toxin C3a is 100 times more potent than C4a, it is unlikely that this
increase of C4a is of any clinical significance for dialysis patients.
Unfortunately, the extremely high levels preclude the detection of
minor C4a increments during hemodialysis. Our in vitro data,
however, clearly show that C4a increases and hence C4 is rapidly
activated upon incubation of serum with cuprophane.
The two isotypes of human complement C4 differ in their
reactivity with acceptor surfaces [14]. Both isotypes react with
hydroxyl and amino groups. However, whereas C4A preferentially
binds to amino groups after activation via its internal thioester,
C4B reacts with hydroxyl groups [29]. As cellulosic membranes
like cuprophane contain abundant hydroxyl groups, one would
expect C4B to be predominantly involved in complement activa-
tion by such membranes. We therefore included a dialysis patient
with a complete deficiency of the isotype C4B in our in vivo study.
The time course of complement activation in this patient was
identical to that of the patient having both isotypes. In the in vitro
studies C4B-deficient serum was somewhat more efficient than
C4A-deficient serum. We assume that C4A may be more effective
in mediating rapid complement activation by cuprophane.
Cleavage of C4 and C2 to form the classical pathway C3-
convertase C4b2a is brought about either by the classical pathway
or lectin pathway of complement [30]. Activation of the classical
pathway requires binding of C1q to the cuprophane membrane.
The classical pathway is usually activated by binding of C1q
through its globular non-collagenous heads to IgG or IgM.
Anti-dextran antibodies of IgG isotype, which are present in
normal serum, have been shown to bind to cuprophane, and their
titer correlates with complement activation [31]. Classical pathway
activation may be started by these anti-dextran antibodies or other
natural polyreactive anti-polysaccharide antibodies of IgG or IgM
isotypes. Our studies of a patient with severe secondary immuno-
globulin deficiency point to a role of immunoglobulin in the initial
phase of complement activation by cuprophane. Although classi-
cal and alternative pathway hemolytic activities were normal, this
patient exhibited delayed and only weak complement activation
during cuprophane hemodialysis. Lymphocytes do not express
anaphylatoxin receptors [30]. An influence, however, of the
extremely high leukocyte count on the plasma levels of C3a and
TCC cannot be excluded. Using the patient’s serum, complement
activation in vitro was also severely impaired, but could be
normalized by preincubation of cuprophane with immunoglobu-
lins. Anti-polysaccharide antibodies present in the immunoglob-
ulin preparation had probably bound to the cuprophane surface
and activated the otherwise intact classical pathway of the patient.
In addition, the somewhat greater efficacy of C4A indicates that
activated C4b binds to amino groups of antibodies on the mem-
brane rather than to hydroxyl groups of the membrane itself [14].
Clearly the role, isotype and specificity of immunoglobulins
involved in complement activation by cuprophane requires further
investigation.
To further establish the involvement of the classical pathway in
complement activation by cuprophane, in vitro experiments using
sera incubated with MgEGTA, an inhibitor of the classical
pathway, were performed. In these experiments it could clearly be
demonstrated that blocking the classical pathway with MgEGTA
results in delayed complement activation identical to C4 defi-
ciency or immunoglobulin deficiency.
In conclusion, our data imply that the rapid activation of
complement by cuprophane depends on the classical pathway.
Based on our results we propose the following extended
concept of complement activation by cellulosic hemodialysis
membranes, which is based on four steps: (a) binding of anti-
polysaccharide antibodies, (b) classical pathway activation, (c)
consecutive alternative pathway activation, and (d) terminal path-
way activation (Fig. 7). Immediately after blood enters the
dialyzer anti-polysaccharide antibodies bind to the membrane.
Then C1q reacts with these immunoglobulins and C4 is cleaved
into C4a and C4b by C1s in the C1 complex. C4b probably binds
Fig. 7. Schematic view of an extended model of complement activation by
cuprophane.
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covalently to amino groups of the antibodies. After binding and
cleavage of C2 the classical pathway C3-convertase C4b2a is
formed. The classical pathway C3-convertase activates C3 by
proteolytic cleavage into C3a and C3b, which is deposited on the
membrane. In addition, C4b protects C3b from cleavage by
Factors H and I. Binding and activation of Factor B creates the
alternative pathway C3-convertase C3bBb, which serves as the
nidus for explosive complement activation by the amplification
loop of the alternative pathway. Cleavage of C5 and terminal
pathway activation is mediated both by the classical pathway
C5-convertase C4b2a3b and the alternative pathway C5-conver-
tase C3bBb3b. In patients with complete C4 deficiency without a
functioning classical pathway, the initial C3b deposition depends
on spontaneous binding of C3b created by C3(H2O)Bb in the fluid
phase. Because this is a rather inefficient and slow process,
complement activation by cuprophane is delayed in these patients.
ACKNOWLEDGMENTS
We are indebted to Friedrich Neumair and Gertraud Beck, who helped
in the hemodialysis studies of C4-deficient patients, and to Anna Schlo¨gl
and Andrea Eder for technical assistance.
Reprint requests to Dr. Karl Lhotta, Nephrologisches Labor, Medizinische
Universita¨tsklinik, Anichstrasse 35, A-6020 Innsbruck, Austria.
E-mail: Karl.Lhotta@uibk.ac.at
APPENDIX
Abbreviations used in this article are: C3a and C5a, anaphylatoxins; C4,
complement component that is a 200 kDa glycoprotein; C4A and C4B,
complement C4 isotypes; EDTA, ethylenediaminetetraacetate; IL-1B,
interleukin-1B; MgEGTA, meagnesium ethylene glycol tetra-acetic acid;
TCC, terminal complement complex; TNF-a, tumor necrosis factor alpha.
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